<table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.02565.005</object-id><label>Table 1.</label><caption><p>Model input parameters<xref ref-type="table-fn" rid="tblfn1">*</xref></p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.02565.005">http://dx.doi.org/10.7554/eLife.02565.005</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>Value</th><th>Reference(s)/Rationale</th></tr></thead><tbody><tr><td colspan="3"><italic>TB and HIV Transmission</italic></td></tr><tr><td>Transmission rate, per smear-positive/highly  infectious person-year</td><td/><td>Calibrated to user-defined TB incidence<xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td></tr><tr><td>Proportional reduction in per-case transmission  rate, MDR-TB</td><td/><td>Calibrated to user-defined MDR-TB prevalence<xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td></tr><tr><td>Proportional reduction in fitness,  isoniazid-monoresistant TB</td><td>25% of MDR-TB reduction</td><td>Assumption</td></tr><tr><td>HIV incidence rate, per year</td><td/><td>Calibrated to user-defined HIV prevalence<xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td></tr><tr><td>Relative transmission rate from  smear-negative/less infectious TB</td><td>0.22</td><td>(<xref ref-type="bibr" rid="bib4">Behr et al., 1999</xref>)</td></tr><tr><td>Proportion of pulmonary TB that is  smear-positive/highly infectious</td><td/><td/></tr><tr><td>&#8195;HIV-negative</td><td>0.63</td><td>(<xref ref-type="bibr" rid="bib39">Steingart et al., 2006a</xref>; <xref ref-type="bibr" rid="bib40">Steingart et al., 2006b</xref>)</td></tr><tr><td>&#8195;HIV-infected</td><td>0.50</td><td>(<xref ref-type="bibr" rid="bib24">Getahun et al., 2007</xref>)</td></tr><tr><td colspan="3"><italic>TB Progression</italic></td></tr><tr><td>Endogenous reactivation rate</td><td/><td/></tr><tr><td>&#8195;HIV-negative</td><td>0.0005/year</td><td>(<xref ref-type="bibr" rid="bib25">Horsburgh et al., 2010</xref>)</td></tr><tr><td>&#8195;HIV-infected</td><td>0.05/year</td><td>(<xref ref-type="bibr" rid="bib3">Antonucci et al., 1995</xref>)</td></tr><tr><td>Proportion of recent infections resulting in  rapid progression</td><td/><td/></tr><tr><td>&#8195;HIV-negative</td><td>0.14</td><td>(<xref ref-type="bibr" rid="bib47">Vynnycky and Fine, 1997</xref>; <xref ref-type="bibr" rid="bib20">Dye et al., 1998</xref>)</td></tr><tr><td rowspan="2">&#8195;HIV-infected</td><td>0.47</td><td>0.75 without ART, (<xref ref-type="bibr" rid="bib16">Daley et al., 1992</xref>)</td></tr><tr><td/><td>75% reduction if on ART, (<xref ref-type="bibr" rid="bib50">Williams et al., 2010</xref>) 50% ART coverage</td></tr><tr><td>Reduction in TB rapid progression probability  due to latent TB infection (HIV-negative only)</td><td>0.79</td><td>(<xref ref-type="bibr" rid="bib2">Andrews et al., 2012</xref>)</td></tr><tr><td colspan="3"><italic>TB Mortality and Resolution</italic></td></tr><tr><td>Life expectancy at age 15</td><td>55 years</td><td>(<xref ref-type="bibr" rid="bib52">World Bank, 2012</xref>)</td></tr><tr><td>Annual mortality from HIV</td><td>0.05/year</td><td>(<xref ref-type="bibr" rid="bib45">UNAIDS, 2012</xref>)</td></tr><tr><td>Annual mortality from TB</td><td/><td/></tr><tr><td>&#8195;HIV-negative, smear-positive/highly infectious</td><td>0.23/year</td><td>(<xref ref-type="bibr" rid="bib44">Tiemersma et al., 2011</xref>)</td></tr><tr><td>&#8195;HIV-negative, smear-negative/less infectious</td><td>0.07/year</td><td>(<xref ref-type="bibr" rid="bib44">Tiemersma et al., 2011</xref>)</td></tr><tr><td>&#8195;HIV-infected</td><td>1.0/year</td><td>(<xref ref-type="bibr" rid="bib12">Corbett et al., 2003</xref>; <xref ref-type="bibr" rid="bib14">Corbett et al., 2007</xref>; <xref ref-type="bibr" rid="bib51">Wood et al., 2007</xref>)</td></tr><tr><td>Rate of spontaneous TB resolution  (HIV-negative only)</td><td/><td/></tr><tr><td>&#8195;Smear-positive/highly infectious</td><td>0.1/year</td><td>(<xref ref-type="bibr" rid="bib44">Tiemersma et al., 2011</xref>)</td></tr><tr><td>&#8195;Smear-negative/less infectious</td><td>0.27/year</td><td>(<xref ref-type="bibr" rid="bib44">Tiemersma et al., 2011</xref>)</td></tr><tr><td colspan="3"><italic>TB Treatment Outcomes and Emergence of Drug Resistance</italic></td></tr><tr><td>Probability of failure or relapse (within 1 year)</td><td/><td/></tr><tr><td>&#8195;Drug-susceptible</td><td>0.04</td><td>(<xref ref-type="bibr" rid="bib55">World Health Organization, 2012</xref>)</td></tr><tr><td>&#8195;INH-monoresistant, first-line therapy</td><td>0.21</td><td>(<xref ref-type="bibr" rid="bib32">Menzies et al., 2009b</xref>)</td></tr><tr><td>&#8195;INH-monoresistant, retreatment or 2nd-line</td><td>0.16</td><td>(<xref ref-type="bibr" rid="bib32">Menzies et al., 2009b</xref>)</td></tr><tr><td>&#8195;MDR-TB, first-line or retreatment</td><td>0.50</td><td>(<xref ref-type="bibr" rid="bib21">Espinal et al., 2000</xref>)</td></tr><tr><td>&#8195;MDR-TB, second-line therapy</td><td>0.30</td><td>(<xref ref-type="bibr" rid="bib53">World Health Organization, 2010</xref>)</td></tr><tr><td>Proportion of one-year recurrence due to failure</td><td/><td/></tr><tr><td>&#8195;Drug-susceptible</td><td>0.14</td><td>(<xref ref-type="bibr" rid="bib29">Lew et al., 2008</xref>)</td></tr><tr><td>&#8195;INH-monoresistant</td><td>0.33</td><td/></tr><tr><td>&#8195;MDR-TB</td><td>0.56</td><td/></tr><tr><td>Probability of acquired drug resistance  (per treatment course)</td><td/><td/></tr><tr><td>&#8195;Susceptible becoming INH-monoresistant</td><td>0.001</td><td>(<xref ref-type="bibr" rid="bib33">Menzies et al., 2009a</xref>; <xref ref-type="bibr" rid="bib32">Menzies et al., 2009b</xref>)</td></tr><tr><td>&#8195;Susceptible becoming MDR-TB</td><td>0.002</td><td/></tr><tr><td>&#8195;INH-monoresistant becoming MDR-TB</td><td>0.045</td><td/></tr><tr><td>&#8195;If treated with 2 effective drugs for &gt;6 mos</td><td>0.017</td><td/></tr><tr><td colspan="3"><italic>Behavioral Parameters</italic></td></tr><tr><td>Infectious months before starting to seek care</td><td/><td/></tr><tr><td>&#8195;HIV-negative</td><td>9 months</td><td>(<xref ref-type="bibr" rid="bib19">Dowdy et al., 2013</xref>)</td></tr><tr><td>&#8195;HIV-infected</td><td>1 month</td><td>(<xref ref-type="bibr" rid="bib13">Corbett et al., 2004</xref>)</td></tr><tr><td>Diagnostic frequency while seeking care</td><td>5.0/year</td><td>(<xref ref-type="bibr" rid="bib41">Storla et al., 2008</xref>; <xref ref-type="bibr" rid="bib38">Sreeramareddy et al., 2009</xref>)</td></tr><tr><td>Probability of treatment in a TB patient  whose microbiological test is negative</td><td>0.25</td><td>(<xref ref-type="bibr" rid="bib49">Wilkinson et al., 2000</xref>; <xref ref-type="bibr" rid="bib18">Dowdy et al., 2008</xref>)</td></tr><tr><td>Loss to follow-up between diagnostic  presentation and treatment initiation</td><td/><td/></tr><tr><td>&#8195;Sputum smear or GXP (not same-day)</td><td>0.15</td><td>(<xref ref-type="bibr" rid="bib30">MacPherson et al., 2014</xref>)</td></tr><tr><td>&#8195;Culture (microcolony or commercial liquid)</td><td>0.25</td><td>(<xref ref-type="bibr" rid="bib18">Dowdy et al., 2008</xref>)</td></tr><tr><td>&#8195;Same-day diagnosis</td><td>0</td><td>Assumption</td></tr><tr><td colspan="3"><italic>Diagnostic Accuracy</italic></td></tr><tr><td>Sensitivity for smear-negative/less-infectious TB</td><td/><td/></tr><tr><td>&#8195;Sputum smear microscopy</td><td>0</td><td/></tr><tr><td>&#8195;Xpert MTB/RIF</td><td>0.72</td><td>(<xref ref-type="bibr" rid="bib9">Brownell et al., 2012</xref>)</td></tr><tr><td>&#8195;Culture (microcolony or commercial liquid)</td><td>0.85</td><td>(<xref ref-type="bibr" rid="bib15">Cruciani et al., 2004</xref>; <xref ref-type="bibr" rid="bib28">Leung et al., 2012</xref>)</td></tr><tr><td>Specificity for TB</td><td/><td>(<xref ref-type="bibr" rid="bib40">Steingart et al., 2006</xref>; <xref ref-type="bibr" rid="bib7">Boehme et al., 2011</xref>; <xref ref-type="bibr" rid="bib28">Leung et al., 2012</xref>)</td></tr><tr><td>&#8195;Sputum smear microscopy</td><td>0.98</td><td/></tr><tr><td>&#8195;Xpert MTB/RIF</td><td>0.98</td><td/></tr><tr><td>&#8195;Microcolony culture</td><td>0.98</td><td/></tr><tr><td>Sensitivity for drug resistance (if TB detected)</td><td/><td/></tr><tr><td>&#8195;Microcolony culture (rifampin and isoniazid)</td><td>0.98</td><td>(<xref ref-type="bibr" rid="bib35">Minion et al., 2010</xref>)</td></tr><tr><td>&#8195;Xpert MTB/RIF (rifampin only)</td><td>0.94</td><td>(<xref ref-type="bibr" rid="bib7">Boehme et al., 2011</xref>)</td></tr><tr><td>Specificity for drug resistance (if TB detected)</td><td/><td/></tr><tr><td>&#8195;Microcolony culture (isoniazid)</td><td>0.96</td><td>(<xref ref-type="bibr" rid="bib35">Minion et al., 2010</xref>)</td></tr><tr><td>&#8195;Microcolony culture (rifampin)</td><td>0.99</td><td>(<xref ref-type="bibr" rid="bib35">Minion et al., 2010</xref>)</td></tr><tr><td>&#8195;Xpert MTB/RIF (rifampin)</td><td>0.98</td><td>(<xref ref-type="bibr" rid="bib7">Boehme et al., 2011</xref>)</td></tr><tr><td colspan="3"><italic>Diagnostic Delay and non-TB Care-Seeking</italic></td></tr><tr><td>Days from presentation to treatment initiation</td><td/><td/></tr><tr><td>&#8195;Sputum smear or Xpert MTB/RIF</td><td>7 days</td><td>Assume 1 week</td></tr><tr><td>&#8195;Microcolony or commercial liquid culture</td><td>30 days</td><td>(<xref ref-type="bibr" rid="bib7">Boehme et al., 2011</xref>)</td></tr><tr><td>Months of therapy before a failing regimen will  be changed, or before default and recurrence</td><td>6 months</td><td>Assumption</td></tr><tr><td>Annual rate of diagnostic evaluation for TB,  among people who do not have active TB</td><td>0.01/year</td><td>10% of suspects have TB, high-incidence setting</td></tr><tr><td colspan="3"><italic>Cost Parameters (user-defined; values below for comparison purposes only)</italic></td></tr><tr><td>Per-patient cost of TB therapy</td><td/><td/></tr><tr><td>&#8195;First-line</td><td>US$500</td><td>User-defined</td></tr><tr><td>&#8195;Retreatment</td><td>US$1000</td><td>(<xref ref-type="bibr" rid="bib46">Vassall et al., 2011</xref>)</td></tr><tr><td>&#8195;Second-line/MDR</td><td>US$5000</td><td>(<xref ref-type="bibr" rid="bib46">Vassall et al., 2011</xref>)</td></tr><tr><td>&#8195;Outpatient visit (diagnosis or follow-up)</td><td>US$10</td><td>(<xref ref-type="bibr" rid="bib46">Vassall et al., 2011</xref>)</td></tr><tr><td>Per-test cost:</td><td/><td/></tr><tr><td>&#8195;Sputum smear</td><td>US$2</td><td>(<xref ref-type="bibr" rid="bib46">Vassall et al., 2011</xref>)</td></tr><tr><td>&#8195;Same-day sputum smear</td><td>US$10</td><td>Assumption</td></tr><tr><td>&#8195;Xpert MTB/RIF</td><td>US$15</td><td>(<xref ref-type="bibr" rid="bib46">Vassall et al., 2011</xref>)</td></tr><tr><td>&#8195;Same-day Xpert MTB/RIF</td><td>US$30</td><td>Assumption</td></tr><tr><td>&#8195;Microcolony culture (with DST)</td><td>US$5</td><td>(<xref ref-type="bibr" rid="bib37">Solari et al., 2011</xref>)</td></tr><tr><td>&#8195;Commercial liquid-media culture</td><td>US$20</td><td>(<xref ref-type="bibr" rid="bib46">Vassall et al., 2011</xref>)</td></tr><tr><td>&#8195;Commercial liquid-media culture + DST</td><td>US$40</td><td>(<xref ref-type="bibr" rid="bib46">Vassall et al., 2011</xref>)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>*</label><p>In the actual model program (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1</xref>), users can change any parameter based on local values.</p></fn><fn id="tblfn2"><label>&#8224;</label><p>For reference, the transmission rate (in infections per person-year during diagnosis-seeking active TB) is 36.9 in the reference scenario, 14.0 in the low-incidence scenario, 25.4 in the high MDR scenario, and 12.9 in the high HIV scenario. Corresponding proportional reductions in MDR-TB transmission rate are 0.23, 0.23, 0.21, and 0.19; and HIV incidence estimates (per 1000 adult person-years) are 0.7, 0.6, 0.6, and 18.9.</p></fn></table-wrap-foot></table-wrap>